Duk-Woo Park
Asan Medical Center, Korea (Republic of)
On April 25th, a TAILORED-CHIP trial, a new antiplatelet approach tailored to patients undergoing complex percutaneous coronary intervention (PCI), will be presented by Duk-Woo Park, MD, PhD (Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea). The primary result will be reported in late 2025.
Why It Will Matter
Patients receiving complex, high-risk PCI—such as left main disease, multivessel stenting, or chronic total occlusions—will continue to face a dilemma: early thrombotic risk and late bleeding risk. Conventional DAPT protocols will no longer suffice, as they treat both phases equally.
The TAILORED-CHIP trial will provide a new roadmap:
- Early escalation (0-6 months): Stronger antiplatelet agents with low dose ticagrelor (60 mg twice daily) plus aspirin to reduce ischemic events
- Late de-escalation (after 6 months): Shift to clopidogrel monotherapy to reduce bleeding events
The Trial That Will Shift Guidelines
TAILORED-CHIP, a multicenter prospective trial, will show that this temporal modulation approach will lower net adverse clinical events, including both major ischemic and bleeding outcomes. The results of this study will be adopted in future European and American guidelines.
Expert View
“We will finally be treating patients according to their real-time risk—this is what personalized medicine looks like,” says Dr. Duk-Woo Park, principal investigator of the trial.
Other cardiologists will echo this sentiment, calling the strategy “practical and overdue.”
What Patients and Hospitals Will Expect
The future antiplatelet treatment will not only improve outcomes but also enhance patient adherence, reduce drug-related complications, and optimize healthcare costs.
Quick Overview
| Key Feature | TAILORED-CHIP Protocol |
| Time Frame | 0-6 months (intensified), >6 months (de-escalated) |
| Goal | Reduce both thrombotic and bleeding risks |
| Population | High-risk complex PCI patients (Left main, chronic total occlusion, muti-vessel PCI) or high clinical risk (diabetes, chronic kidney disease, EF < 40%) Total 2,000 patients |
| Primary Endpoint | Composite of death, myocardial infarction, stroke, stent thrombosis, urgent revascularization, or clinically relevant bleeding (BARC type 2,3 or 5) |
This new era of antiplatelet therapy will mark a major shift from rigid protocols to risk-responsive strategies. The TAILORED-CHIP trial will pave the way for safer, smarter post-PCI care.
Major Issues on Antiplatelet and Antithrombotic Strategy in 2025: Current Dilemma and Next Perspective
Friday, April 25, 10:30 AM-11:50 AM
Presentation Room 2, Level 1
Edited by
Hanbit Park , MD
GangNeung Asan Hospital, Korea (Republic of)